TP53 and cancer: The differences can be attributed to several reasons: this variant was included in our internal therapeutic database, it was a nonsynonymous SNV in the exonic region of TP53, it was absent in the population databases (extremely low MAF), it was present in ICGC, it was predicted as damaging by seven tools, TP53 was involved in a critical cancer-associated pathway, and there was a “pathogenic” record of this variant in ClinVar.